Filing Details

Accession Number:
0001140361-25-004495
Form Type:
13G Filing
Publication Date:
2025-02-13 19:00:00
Filed By:
Kluge Andreas
Company:
Telix Pharmaceuticals Ltd
Filing Date:
2025-02-14
SEC Url:
13G Filing
Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name Beneficially Owned Number of Shares Beneficially Owned Number of Aggregate Shares Percent of Class
Kluge Andreas 0 22,675,000 6.78%
Gnosis Verwaltungsgesellschaft m.b.H. 0 22,675,000 6.78%
Filing





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox checked   Rule 13d-1(d)






SCHEDULE 13G



Comment for Type of Reporting Person:  (1) Footnote to Row 11: Based on 334,683,357 ordinary shares outstanding as of September 30, 2024, as reported in the Form 20-F filed by the Issuer with the Securities and Exchange Commission on October 17, 2024.


SCHEDULE 13G



Comment for Type of Reporting Person:  (1) Footnote to Row 11: Based on 334,683,357 ordinary shares outstanding as of September 30, 2024, as reported in the Form 20-F filed by the Issuer with the Securities and Exchange Commission on October 17, 2024.


SCHEDULE 13G


 
Kluge Andreas
 
Signature:/s/ Dr. Andreas Kluge
Name/Title:Dr. Andreas Kluge
Date:02/14/2025
 
Gnosis Verwaltungsgesellschaft m.b.H.
 
Signature:/s/ Dr. Andreas Kluge
Name/Title:Dr. Andreas Kluge, Managing Director
Date:02/14/2025